|
 |
Our Science Agenda |
|
|
| |
Current CPCRA TrialsCPCRA 066: Genomics Description: The purpose of this study is to obtain a whole blood sample to archive for use in future studies investigating associations between human genetic factors and clinical data collected in qualifying CPCRA studies for the purpose of addressing questions related to HIV-infection or conditions relevant to the health of persons with HIV-infection. This study is open to enrollment. CPCRA 065: The SMART Study The purpose of this study is to compare
the long-term clinical consequences of two strategies of antiretroviral
(AR) management: the drug conservation (DC) strategy, a strategy
aimed at conserving drugs through episodic use of antiretroviral
treatment for the minimum time to maintain CD4+ cell count >= 250
cells/mm3 versus the viral suppression (VS) strategy, a strategy
aimed at suppressing viral load as much as possible, immediately
following randomization and throughout follow-up, irrespective of
CD4+ cell count. This study is closed to accrual, patients are in followup. CPCRA 060: Long-Term Monitoring This study is designed to provide a
mechanism for long-term monitoring of (1) participants currently
or previously enrolled in qualifying randomized trials of HIV treatment
or management strategies, (2) antiretroviral-naive patients starting
treatment outside a qualifying CPCRA trial, and (3) antiretroviral-naive
patients electing to defer treatment. This study is closed to accrual,
patients are in followup. ESPRIT ESPRIT is a randomized, international,
5-year, 4000-person study of interleukin-2 (IL-2) in people with
HIV infection and a CD4+ (also called T4) cell count of at least
300/mm3. The goal of study is to evaluate and compare the effectiveness
of IL-2 plus anti-HIV therapy versus anti-HIV therapy alone on numbers
and severity of AIDS-related illnesses and deaths over a 5-year
period. This study is closed to accrual, patients are in followup.
|